Clindacin vaginal suppositories 100mg, No. 3

Bacterial vaginosis caused by microorganisms sensitive to clindamycin.

Intravaginally. Before use, one suppository is freed from the contour packaging, after cutting the film along the contour of the suppository, it is inserted, if possible, deep into the vagina, in the supine position.
1 suppository 1 time per day, immediately before bedtime for 3-7 days in a row.

1 suppository contains:

active substance - clindamycin phosphate in terms of clindamycin - 100 mg

excipients : semi-synthetic glycerides (like 'Estarinum', 'Witepsol' or 'Suppocir').

Hypersensitivity, pregnancy 1 trimester. Application during pregnancy and lactation Clindamycin crosses the placenta into the circulatory system of the fetus. Excreted in breast milk. Intravaginal use of clindamycin during pregnancy is possible only if the intended benefit to the mother outweighs the potential risk to the fetus.
It is recommended to be careful when prescribing to lactating women (during treatment, breastfeeding is stopped).

Trade name of the drug: ClindacinЃ

International non-proprietary name:

Clindamycin

Dosage form:

vaginal suppositories

Composition:

1 suppository contains:

active substance - clindamycin phosphate in terms of clindamycin - 100 mg

excipients: semi-synthetic glycerides (such as Estarinum, Witepsol or Supposir).

Description.
White or white with a yellowish tinge, suppositories of a cylindrical conical shape. There are no inclusions on the longitudinal cut, the presence of an air and porous rod and a funnel-shaped depression is allowed.

Pharmacotherapeutic group:

The antibiotic is lincosamide.

ATX code: G01AA10.

pharmachologic effect

A bacteriostatic antibiotic from the group of lincosamides, has a broad spectrum of action, binds to the 50S subunit of the ribosomal membrane and suppresses protein synthesis in the microbial cell. In relation to a number of gram-positive cocci, a bactericidal effect is possible.

Active against Staphylococcus spp. (including Staphylococcus epidermidis, producing and non-producing penicillinase), Streptococcus spp. (excluding Enterococcus faecalis), Streptococcus pneumoniae, Corynebacterium diphtheriae, Mycoplasma spp, anaerobic and microaerophilic gram-positive cocci (including Peptococcus spp. and Peptostreptococcus spp.), Clostridium perfringens, Bpp. spp. (including Bacteroides fragilis and Prevotella melaninogenica), Fusobacterium spp., Propionibacterium spp., eubacterium and Actinomyces israelii.

Most strains of Clostridium perfringens are susceptible to clindamycin, but other Clostridium spp. (including Clostridium sporogenes, Clostridium tertium) are resistant to its action, therefore, in case of infections caused by Clostridium spp., it is recommended to determine the antibiogram.

Cross-resistance exists between clindamycin and lincomycin.

Pharmacokinetics
After a single intravaginal injection of 100 mg of clindamycin, 4% of the administered dose undergoes systemic absorption. The maximum plasma concentration is 20 ng / ml.

Indications
Bacterial vaginosis caused by microorganisms sensitive to clindamycin.

Contraindications
Hypersensitivity, pregnancy 1 trimester. Application during pregnancy and lactation Clindamycin crosses the placenta into the circulatory system of the fetus. Excreted in breast milk. Intravaginal use of clindamycin during pregnancy is possible only if the intended benefit to the mother outweighs the potential risk to the fetus.
It is recommended to be careful when prescribing to lactating women (breastfeeding is stopped for the duration of treatment).

Method of administration and dosage
Intravaginally. Before use, one suppository is freed from the contour packaging, after cutting the film along the contour of the suppository, it is inserted, if possible, deep into the vagina, in the supine position.
1 suppository 1 time per day, immediately before bedtime for 3-7 days in a row.

Side effects
From the genitourinary system: cervicitis, vaginitis, vulvovaginal irritation.
From the side of hematopoiesis: rarely reversible leukopenia, neutropenia, eosinophilia, agranulocytosis, thrombocytopenia.
Allergic reactions: maculopapular rash, urticaria, itching.
With resorption, there is a possibility of developing systemic side effects, including, in rare cases, pseudomembranous enterocolitis.

Overdose
Due to low absorption of the drug Overdose is unlikely.

Interaction
Enhances the action of drugs rifampicin, aminoglycosides - streptomycin, gentamicin, deepens the muscle relaxation caused by n-anticholinergics.
Incompatible with erythromycin, ampicillin, diphenylhydantoin, barbiturates, aminophylline, calcium gluconate and magnesium sulfate.

Special instructions
Vaginal suppositories are not recommended to be used simultaneously with other intravaginal drugs.
The drug does not affect the reaction rate of vehicle drivers and persons serving installations requiring special attention.

Release form
Vaginal suppositories 100 mg.
3 suppositories in a blister strip packaging. 1 blister strip packaging together with instructions for use is placed in a carton box.

Storage conditions
In a dry, dark place at a temperature of 15 to 25 ? C.
Keep out of the reach of children.

Shelf life is
3 years. Do not use after the expiration date.

Terms of dispensing from pharmacies
Without prescription.